Alnylam Pharmaceuticals’ Post

We are pleased to share Medicenna President and CEO Fahar Merchant's presentation of the Company's clinical updates on MDNA11 at the Oncology Innovation Forum last month, ahead of the American Society of Clinical Oncology 2024 Meeting. MDNA11, being evaluated in the Phase 1/2 ABILITY-1 Study, is the only non-alpha beta-enhanced IL-2 immunotherapy in clinical development. MDNA11 continues to demonstrate its best-in-class potential with differentiated deep and durable single agent activity in patients with advanced solid tumors who have failed checkpoint therapy. Sachs Associates video below accompanies the presentation on MDNA11. Read the full release for more information: https://lnkd.in/dR44hYaW #Immunotherapy #Oncology #Biotech #ClinicalTrial #AdvancedTumors

$MDNAF $MDNA.to We expect to provide a comprehensive data-set on monotherapy from MDNA11 dose-expansion trial And some topline data on combo trial with #Ketruda Finally Sachs shared another great presentation by Dr. Fahar, MDNA's CEO at the 10th Annual Oncology Innovation Forum!

Today Halia’s CEO David Bearss Ph.D. presented at the 5th Inflammasome Therapeutics Summit in Boston about Halia’s efforts to combat chronic inflammation by inhibiting the inflammasome NLRP3. Dave discussed the early clinical evaluation of Halia’s NLRP3 inhibitor, HT-6184, and its activity as a selective, orally bioavailable, allosteric inhibitor of Nek7/NLRP3. To read more about the results of Halia’s completed Phase 1 clinical trial (NCT05447546), see today’s news release here: https://prn.to/3sV4T4T For more information about the Summit, go to: https://bit.ly/40UyYOI #inflammasome #chronicinflammation #inflammasometherapeuticssummit #NLRP3 #therapeutics

Today, Halia Therapeutics announced that David Bearss Ph.D., President and CEO of Halia, will be presenting and participating in a panel discussion at the 5th Inflammasome Therapeutics Summit. The Summit is taking place on November 28-30, in Boston, MA. To read the full release, visit: https://prn.to/49NjLTM #inflammasome #chronicinflammation #NLRP3 #therapeutics #halia #newsrelease #therapeuticssummit

With such brilliant panel of experts you just can't afford to miss this webinar! #ESMO #PrecisionOncology #biomarkers

CONFERENCE UPDATE: The abstract is available for Repare Therapeutics' presentation at ESMO GI from the Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI. Learn more here: https://lnkd.in/ebPvugmb #precisiononcology #syntheticlethality #clinicaltrials

Today! Last chance to join this webinar. Dr Torsten Wuestefeld and Dr Si Hui Tan from Lerna Biopharma (Formerly known as Cargene Therapeutics) discuss how they are using #siRNA as a modality to accelerate therapeutic development for liver #diseases with high unmet needs in this upcoming webinar. Register here: https://hubs.li/Q027ppn40 #siRNA #liverdisease SelectScience®

Back-to-back development candidates progressing into the clinic is no mean feat! Following on the footsteps of VYN201 which progressed into Phase 2b last month; this week we are delighted to share that dosing of the first participants in the Phase 1a trial of VYN202 has taken place. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immuno-inflammatory diseases. VYN202 was discovered by the team at Tay Therapeutics before being licensed to VYNE Therapeutics who are leading clinical development. Top-line data is expected in the second half of 2024. https://lnkd.in/ePG4eb7V https://lnkd.in/eGtRw7Ty

Halia’s CEO David Bearss Ph.D. will be speaking at the 5th Inflammasome Therapeutics Summit in Boston about Halia’s efforts to combat chronic inflammation by inhibiting the inflammasome NLRP3. Dave will discuss the early clinical evaluation of Halia’s NLRP3 inhibitor, HT-6184, and its activity as a selective, orally bioavailable, allosteric inhibitor of Nek7/NLRP3. For more information about the Summit, go to: https://lnkd.in/et3h9AQd #inflammasome #chronicinflammation #inflammasometherapeuticssummit #NLRP3 #therapeutics

Your one-stop-shop for many things mRNA🤝 ...Don't just take our word for it - check out what some of our expert speakers have to say about the 4th mRNA-Based Therapeutics Summit this July! Get your copy of the three-day program here, jam-packed with four tracks' worth of mRNA content: https://ter.li/s9qfa7 #mRNA #mRNATherapeutics #mRNAVaccines #RNA #WorldRNA #mRNASummit